Jyi Cheng Ng, MD
@JyiChengNg
Halsted Intern @hopkinssurgery | CRS Research Fellow @MayoClinicSurg | @IASSS_1 Office | ✝️🇲🇾
Can’t do a #GenSurgMatch2025 post without @DrDavidLarson @KellieLMathisMD @YWLum! I wouldn’t be where I am today without ✝️ and I’m especially blessed with mentors who’re invested in my growth. Grateful for EVERYONE I’ve crossed paths with and the opportunities along the way!!!




A study led by @MayoClinic clinicians shows that neoadjuvant chemotherapy (NAC) improves 5-year survival in locally advanced #ColonCancer. Analysis of 8 control trials supports NAC as a safe, effective alternative with high-quality evidence. Learn more: bit.ly/4mhoTVB
📣📣Excited to share our publication in @AnnSurgOncol on the impact of RAS/BRAF mutations on pCR in rectal cancer in the TNT era. 🟢 Mutations associated with: ⬇️ pCR rates ⬇️ DFS Grateful to @DrDavidLarson and all co-authors! @RichardSassun @JyiChengNg @MayoClinicSurg
Today is the last day of fellowship for our senior fellow @AlexisLauria1 ! Congratulations on all that you have accomplished! It has been amazing having you as part of the team and we will all miss you very much! Watch out Georgia! You’ve got a superstar heading over!
Excited to see our meta-analysis of ICC deficits in chronic gastroduodenal disorders, out now in @AmJGastro! 🔬 We show a spectrum of ICC deficits in gastroparesis, FD, and CNVS 👉 an under-appreciated disease mechanism! 🧵 journals.lww.com/ajg/abstract/9…
Huge thanks to the CRS Division and @DrDavidLarson for the opportunity to work on this project!
A study led by @MayoClinic surgeons shows total neoadjuvant therapy followed by surgery to treat advanced #RectalCancer leads to excellent outcomes, including low recurrence and a high percentage of cancer-specific survival. Read the study to learn more: bit.ly/3ZYAakN
ATLS Trauma training for our incoming @hopkinssurgery residents is always a fun learning day. I don’t think they realize the brainpower in some of their airway skill station teachers- 2 of the highest ranking EMS docs in Maryland.
State of the Department at @hopkinssurgery by our chair and genuinely great human being- @AndrewMCameron. Thank your for your leadership in incredibly difficult times. The future is bright. Well deserved research, teaching, clinical, mentoring awards to so many faculty.
Had a such a great time in ISW2024 last year meeting like-minded individuals from around the 🌎 x.com/jyichengng/sta… Don’t miss the opportunity to join #ISW2026 in Mexico City as a FSP delegate! 👇
Applications for the FSP are NOW OPEN!🩺 Join us for the 51st International Surgical Week in Mexico City from 19-23 April 2026🇲🇽 *Applications close:* 30 June 2025 Queries: [email protected] *Link to form: forms.gle/XB6WtaBL6cVfGg…
🔥 Hot off the press in @ejsotweets! Real-world surgical & oncological outcomes of rectal cancer patients treated with TNT followed by TME at @MayoClinicSurg. 🔗: lnkd.in/gmkTV-XK Huge thanks to 🧢 @DrDavidLarson and coauthors @RichardSassun @AnnaclaraS65 @tommyv1992


Great work @JyiChengNg! Showing what the results really are in non-RCT settings
Total neoadjuvant therapy shows promising results for rectal cancer by Ng JC, Sassun R (...) Larson DW et 7 al. in Eur J Surg Oncol 🪡 read our summary 👉 stitches.today/2025/06/17/tot… 📖 read the article: linkinghub.elsevier.com/retrieve/pii/S…
Great news!🔥 In our new RCTs Metanalysis, OS and DFS were improved with Neoadjuvant Chemotherapy compared to Adjuvant Chemotherapy 🔎Trial sequential analysis confirms that the evidence is conclusive. No further RCTs are needed! Link tinyurl.com/2ampyynj @DrDavidLarson @3isac
Diverticulitis' incidence is rising, but surgery is not always recommended, especially for uncomplicated cases. We delved into the relationship of surgery, quality of life, and cytokine levels, revealing a benefit with surgery. Read the full paper here!🔥 onlinelibrary.wiley.com/doi/10.1111/co…
Game-changer at #ASCO25 🔥 Pre-plenary press release!! ATOMIC is the most important adjuvant study yet for MSI-H colon cancer—and it’s practice-changing. 🧬 Stage III dMMR colon cancer 🧪 Atezolizumab + mFOLFOX6 vs mFOLFOX6 alone 💥 3-yr DFS: 86.4% vs 76.6% ⚖️ HR 0.50 | p <…
The Department of Surgery at @MayoClinic is hiring a board-eligible/board-certified #Colorectal surgeon to join our surgical team at @MayoClinic in Rochester. Interested individuals can learn more about the role and apply here: jobs.mayoclinic.org/job/rochester/…
✨EXTENDED✨ Attention trainees! Submit an abstract for the AWS Starr Research Forum at the 2025 AWS Annual Conference. The deadline has been extended to May 29. Interested in reviewing submitted abstracts? Apply to be an abstract reviewer by May 30! womensurgeons.org/starr-research…
🔍 Precision in HPB Surgery: Integrating Technology, Teamwork, and Data to Transform Patient Outcomes...@ZhiVenFongMD 🗓️ 6th of June 2025 | 📍 Zoom 📌 Open to all surgical trainees, residents, and students interested in cancer surgery. Register now! iasss.org/2025/05/15/pre…
🤖 surgery for fistulizing diverticulitis: 1️⃣% conversion 3️⃣% leak 6️⃣% abscess 1️⃣% recurrence Couldn’t ask for a better team 🧑🧑🧒🧢 @MayoClinicSurg
Diverticular colovaginal/vesical fistulas represent a difficult scenario for surgeons. In laparoscopy, 36% of cases are converted🔪 Our study found that robotic surgery yields a 1% conversion rate and recurrence! 🤖 @JyiChengNg @DrDavidLarson @AnnaclaraS65 pubmed.ncbi.nlm.nih.gov/40355739/
It is time to give Tumor Deposit a proper role in the staging - Richard Sassun @RichardSassun @JAMASurgery oncodaily.com/blog/258923-ri… #Cancer #CancerResearch #ColonCancer #Medicine #MedX #MedNews #MedEd #Health #Oncology #OncoDaily
Rectal cancers with no response to TNT exhibit the worst survival outcomes. What features can predict a no response to TNT? 🤔 Find out in our recent article on Annals of Surgical Oncology!!! 👇👇👇 link.springer.com/article/10.124… @JyiChengNg @AnnaclaraS65
May Issue: Predictors of Pathologic Non-response to Neoadjuvant Approaches in Locally Advanced #RectalCancer @JyiChengNg @RichardSassun rdcu.be/elJ6E @csabagajdos1 @SyedAAhmad5
Great work once again from @JyiChengNg and @MayoClinic
Key findings: 🚨 ~13% locally advanced rectal cancer pt were nonresponders 📉 Nonresponders had the worst outcomes 🔍 Pretreatment MR-EMVI predicts pNR Next steps: 🤔 What can we do to improve their outcomes? Grateful to 🧢 @DrDavidLarson for his mentorship & my coauthors